SLCO2B1 and prostate carcinoma: Lastly, there are already currently available clinical and genetic tools and technologies to evaluate prostate cancer outcomes based on HSD3B1, SLCO2B1, and SRD5A2 genotype and their relationships to disease, which will guide future biomarker-driven treatment.